2023 World Conference on Lung Cancer (Posters)-EP13.03. Outcomes of ES-SCLC Patients Treated with Platinum Doublet and Immunotherapy: A Western Australia Retrospective Review

EP13.03. Outcomes of ES-SCLC Patients Treated with Platinum Doublet and Immunotherapy: A Western Australia Retrospective Review - PDF(Abstract)

Back to course

Pdf Summary

This study examined the outcomes and safety profile of patients with extensive-stage small cell lung cancer (ES-SCLC) who were treated with atezolizumab plus platinum-etoposide chemotherapy in a real-world Australian population. The data was collected retrospectively from two centers in Perth, Western Australia, between January 2020 and March 2023. The outcomes assessed included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR). The incidence of immune-related adverse events (irAEs) was also recorded. <br /><br />The study included 101 patients with a median age of 68 years. At baseline, 15.7% had brain metastasis and 49.0% had liver metastasis. The median PFS and OS were 5.0 and 8.5 months, respectively, compared to 5.2 and 12.3 months in the IMpower133 trial. The ORR was similar between the two populations, but the median DOR in the real-world cohort was slightly longer (1.1 months). The incidence of irAEs was 22.7% (grade 3: 11.9%) in the study, compared to 39.9% (grade 3: 10.6%) in the trial. Patients who experienced any grade irAE had better OS and PFS compared to those who did not. <br /><br />Overall, the median OS and PFS in the real-world cohort were shorter than those observed in the IMpower133 trial. However, the real-world cohort had higher ORRs and longer DOR. Poor prognostic factors such as higher ECOG status and the presence of brain and liver metastases likely contributed to the shorter OS and PFS in this real-world setting. The presence of irAEs in the patient population showed improved OS and PFS compared to patients without irAEs. Further investigation is needed to understand the association between irAEs and the efficacy of atezolizumab in ES-SCLC.

Asset Subtitle

Joann Lee

Meta Tag

Speaker Joann Lee

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

extensive-stage small cell lung cancer

atezolizumab

platinum-etoposide chemotherapy

real-world study

Australian population

overall survival

progression-free survival

objective response rate

duration of response

immune-related adverse events